FTC Probes Adderall Settlement Between Barr, Shire

Law360, New York (November 10, 2006, 12:00 AM EST) -- The U.S. Federal Trade Commission is probing an agreement between Barr Pharmaceuticals and Shire PLC that put to rest two patent lawsuits brought by Shire that sought to thwart Barr’s attempts to market a generic version of the hyperactivity drug Adderall XR.

The FTC has asked Barr to save all the documentation regarding the settlement, according to Barr’s Form 10-Q, filed with the U.S. Securities and Exchange Commission on Thursday. Barr said it intends to cooperate with the investigation.

In August, Barr and Shire struck a...
To view the full article, register now.